Dupilumab, a monoclonal antibody that targets IL-4Rα and subsequent IL-4/13 signaling, was approved by the US FDA in 2017 and is recognized as a safe option for long-term use in moderate-to-severe AD. This evidence concerns the gene IL4 and Alzheimer disease.